NASDAQ: APYX | Healthcare / Medical Devices & Instruments / USA |
9.88 | +0.2400 | +2.49% | Vol 120.77K | 1Y Perf 178.93% |
Apr 20th, 2021 16:00 DELAYED |
BID | 8.44 | ASK | 10.08 | ||
Open | 9.55 | Previous Close | 9.64 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 10.33 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 4.55 | Finscreener Ranking | ★★★★ 54.18 | |
Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★★ 56.13 | |
Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★ 45.09 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
Market Cap | 339.06M | Earnings Rating | Strong Buy | |
Price Range Ratio 52W % | 76.85 | Earnings Date | 12th May 2021 |
Today's Price Range 9.459.98 | 52W Range 2.8112.01 | 5 Year PE Ratio Range -13.4015.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 4.66% | ||
1 Month | -7.06% | ||
3 Months | -6.35% | ||
6 Months | 68.60% | ||
1 Year | 178.93% | ||
3 Years | 171.43% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 8.80 | |||
ROE last 12 Months | -16.84 | |||
ROA (5Y Avg) | 5.67 | |||
ROA last 12 Months | -14.30 | |||
ROC (5Y Avg) | 7.45 | |||
ROC last 12 Months | -22.49 | |||
Return on invested Capital Q | -2.36 | |||
Return on invested Capital Y | -17.57 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 1.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-26.80 | ||||
5.19 | ||||
14.56 | ||||
133.80 | ||||
-36.20 | ||||
-0.47 | ||||
5.19 | ||||
1.86 | ||||
289.59M | ||||
Forward PE | -21.90 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
6.50 | ||||
7.20 | ||||
0.00 | ||||
0.01 | ||||
-420.90 | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
63.20 | ||||
-69.90 | ||||
-66.70 | ||||
-38.10 | ||||
-43.94 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
22.71M | ||||
0.66 | ||||
-11.47 | ||||
-4.40 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | -0.13 | -0.04 | 69.23 |
Q03 2020 | -0.16 | -0.13 | 18.75 |
Q02 2020 | -0.17 | -0.14 | 17.65 |
Q01 2020 | -0.22 | -0.06 | 72.73 |
Q04 2019 | -0.19 | -0.16 | 15.79 |
Q03 2019 | -0.18 | -0.13 | 27.78 |
Q02 2019 | -0.18 | -0.13 | 27.78 |
Q01 2019 | -0.18 | -0.14 | 22.22 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | -0.15 | 0.00 | - |
6/2021 QR | -0.14 | 0.00 | - |
12/2021 FY | -0.56 | -9.80 | Negative |
12/2022 FY | -0.44 | 2.22 | Positive |
Next Report Date | 12th May 2021 |
Estimated EPS Next Report | -0.15 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 120.77K |
Shares Outstanding | 34.32M |
Trades Count | 973 |
Dollar Volume | 1.02M |
Avg. Volume | 97.77K |
Avg. Weekly Volume | 111.09K |
Avg. Monthly Volume | 101.63K |
Avg. Quarterly Volume | 91.18K |
Apyx Medical Corporation (NASDAQ: APYX) stock closed at 9.88 per share at the end of the most recent trading day (a 2.49% change compared to the prior day closing price) with a volume of 120.77K shares and market capitalization of 339.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 266 people. Apyx Medical Corporation CEO is Charles D. Goodwin.
The one-year performance of Apyx Medical Corporation stock is 178.93%, while year-to-date (YTD) performance is 37.22%. APYX stock has a five-year performance of %. Its 52-week range is between 2.81 and 12.01, which gives APYX stock a 52-week price range ratio of 76.85%
Apyx Medical Corporation currently has a PE ratio of -26.80, a price-to-book (PB) ratio of 5.19, a price-to-sale (PS) ratio of 14.56, a price to cashflow ratio of 133.80, a PEG ratio of 2.32, a ROA of -14.30%, a ROC of -22.49% and a ROE of -16.84%. The company’s profit margin is -43.94%, its EBITDA margin is -66.70%, and its revenue ttm is $22.71 Million , which makes it $0.66 revenue per share.
Of the last four earnings reports from Apyx Medical Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Apyx Medical Corporation’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Apyx Medical Corporation is Moderate Buy (2), with a target price of $10.33, which is +4.55% compared to the current price. The earnings rating for Apyx Medical Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apyx Medical Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apyx Medical Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.80, ATR14 : 0.63, CCI20 : 6.34, Chaikin Money Flow : 0.03, MACD : -0.05, Money Flow Index : 46.51, ROC : -0.21, RSI : 59.94, STOCH (14,3) : 62.18, STOCH RSI : 0.43, UO : 53.36, Williams %R : -37.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apyx Medical Corporation in the last 12-months were: Charles D. Goodwin (Buy at a value of $93 197), Lawrence J. Waldman (Option Excercise at a value of $15 632), Michael Geraghty (Option Excercise at a value of $21 075)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Strong Buy |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.
CEO: Charles D. Goodwin
Telephone: +1 727 384-2323
Address: 5115 Ulmerton Road, Clearwater 33760, FL, US
Number of employees: 266
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.